Literature DB >> 19898448

What's fueling the biotech engine--2008.

Saurabh Aggarwal1.   

Abstract

Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.

Entities:  

Mesh：

Year:  2009        PMID： 19898448     DOI： 10.1038/nbt1109-987

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  6 in total

1.  What's fueling the biotech engine-2007.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2008-11       Impact factor: 54.908

2.  What's fueling the biotech engine?

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

3.  Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Richard F Spaide; Ketan Laud; Howard F Fine; James M Klancnik; Catherine B Meyerle; Lawrence A Yannuzzi; John Sorenson; Jason Slakter; Yale L Fisher; Michael J Cooney
Journal:  Retina       Date:  2006-04       Impact factor: 4.256

4.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

Authors:  Kenneth R Carson; Andrew M Evens; Elizabeth A Richey; Thomas M Habermann; Daniele Focosi; John F Seymour; Jacob Laubach; Susie D Bawn; Leo I Gordon; Jane N Winter; Richard R Furman; Julie M Vose; Andrew D Zelenetz; Ronac Mamtani; Dennis W Raisch; Gary W Dorshimer; Steven T Rosen; Kenji Muro; Numa R Gottardi-Littell; Robert L Talley; Oliver Sartor; David Green; Eugene O Major; Charles L Bennett
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

5.  Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.

Authors:  J M Jonasson; R Ljung; M Talbäck; B Haglund; S Gudbjörnsdòttir; G Steineck
Journal:  Diabetologia       Date:  2009-07-09       Impact factor: 10.122

6.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122
  6 in total
  14 in total

1.  What's fueling the biotech engine--2010 to 2011.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2011-12-08       Impact factor: 54.908

2.  Therapeutic antibodies: past, present and future.

Authors:  Olive Leavy
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 3.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

4.  What's fueling the biotech engine-2009-2010.

Authors:  Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

5.  [Biologics. Magic bullets - magic effects - magic costs? New therapeutics and their effects].

Authors:  O Frey; T Kamradt
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

6.  What's fueling the biotech engine-2011 to 2012.

Authors:  Saurabh Rob Aggarwal
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

7.  What's fueling the biotech engine-2012 to 2013.

Authors:  Rob Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

Review 8.  Molecular pharming's foot in the FDA's door: Protalix's trailblazing story.

Authors:  Tsafrir S Mor
Journal:  Biotechnol Lett       Date:  2015-07-07       Impact factor: 2.461

Review 9.  Computational design of protein-ligand interfaces: potential in therapeutic development.

Authors:  Andrew Morin; Jens Meiler; Laura S Mizoue
Journal:  Trends Biotechnol       Date:  2011-02-04       Impact factor: 19.536

Review 10.  Size matters: gold nanoparticles in targeted cancer drug delivery.

Authors:  Erik C Dreaden; Lauren A Austin; Megan A Mackey; Mostafa A El-Sayed
Journal:  Ther Deliv       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.